AstraZeneca plc (NYSE:AZN) Shares Sold by Pictet North America Advisors SA

Pictet North America Advisors SA lessened its holdings in shares of AstraZeneca plc (NYSE:AZN) by 10.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 215,507 shares of the company’s stock after selling 25,467 shares during the period. AstraZeneca accounts for approximately 2.6% of Pictet North America Advisors SA’s investment portfolio, making the stock its 14th biggest holding. Pictet North America Advisors SA’s holdings in AstraZeneca were worth $17,658,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC lifted its holdings in shares of AstraZeneca by 0.8% in the 1st quarter. FMR LLC now owns 56,832,723 shares of the company’s stock valued at $2,297,746,000 after buying an additional 458,752 shares during the period. Primecap Management Co. CA lifted its holdings in shares of AstraZeneca by 0.3% in the 1st quarter. Primecap Management Co. CA now owns 56,343,156 shares of the company’s stock valued at $2,277,954,000 after buying an additional 195,230 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of AstraZeneca by 3.4% in the 2nd quarter. Fisher Asset Management LLC now owns 15,904,291 shares of the company’s stock valued at $656,529,000 after buying an additional 529,694 shares during the period. GQG Partners LLC lifted its holdings in shares of AstraZeneca by 72.0% in the 1st quarter. GQG Partners LLC now owns 5,155,269 shares of the company’s stock valued at $207,823,000 after buying an additional 2,157,252 shares during the period. Finally, OppenheimerFunds Inc. lifted its holdings in shares of AstraZeneca by 141.3% in the 1st quarter. OppenheimerFunds Inc. now owns 4,105,290 shares of the company’s stock valued at $165,977,000 after buying an additional 2,403,920 shares during the period. 17.85% of the stock is currently owned by institutional investors and hedge funds.

AZN has been the subject of several recent analyst reports. ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Argus raised their price target on AstraZeneca to $50.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, Pareto Securities raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Three analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $45.96.

AZN stock traded down $0.83 during midday trading on Friday, hitting $44.58. 3,743,273 shares of the stock were exchanged, compared to its average volume of 3,545,438. The stock’s 50-day moving average price is $42.71 and its 200-day moving average price is $40.60. The stock has a market cap of $115.02 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 1.55 and a beta of 0.52. AstraZeneca plc has a fifty-two week low of $35.30 and a fifty-two week high of $45.69. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.75 and a current ratio of 0.95.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.43. The firm had revenue of $5.72 billion during the quarter, compared to analysts’ expectations of $5.57 billion. AstraZeneca had a return on equity of 35.83% and a net margin of 9.38%. AstraZeneca’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.69 earnings per share. Research analysts anticipate that AstraZeneca plc will post 1.81 EPS for the current year.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: The primary rules of Elliott Wave theory

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.